DekaBank Deutsche Girozentrale’s Celldex Therapeutics CLDX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$782K	Hold	25,000	–	–	﹤0.01%	827
2026 Q1	$798K	Hold	25,000	–	–	﹤0.01%	828
2025 Q4	$1.14M	Hold	25,000	–	–	﹤0.01%	853
2025 Q3	$646K	Hold	25,000	–	–	﹤0.01%	940
2025 Q2	$514K	Hold	25,000	–	–	﹤0.01%	979
2025 Q1	$489K	Hold	25,000	–	–	﹤0.01%	978
2024 Q4	$628K	Hold	25,000	–	–	﹤0.01%	958
2024 Q3	$826K	Hold	25,000	–	–	﹤0.01%	923
2024 Q2	$943K	Hold	25,000	–	–	﹤0.01%	889
2024 Q1	$1.03M	Hold	25,000	–	–	﹤0.01%	870
2023 Q4	$994K	Buy	+25,000	New	+$735K	﹤0.01%	900
2018 Q3	–	Sell	-3,720	Closed	-$28K	–	1231
2018 Q2	$28K	Hold	3,720	–	–	﹤0.01%	1193
2018 Q1	$128K	Buy	+3,720	New	+$144K	﹤0.01%	1033
2016 Q2	–	Sell	-3,233	Closed	-$175K	–	1002
2016 Q1	$175K	Sell	3,233 -107	-3%	-$12K	﹤0.01%	868
2015 Q4	$808K	Buy	3,340 +33	+1%	+$7.19K	0.01%	597
2015 Q3	$523K	Buy	3,307 +167	+5%	+$47.3K	0.01%	682
2015 Q2	$1.19M	Buy	3,140 +113	+4%	+$44.9K	0.01%	535
2015 Q1	$1.26M	Sell	3,027 -166	-5%	-$59.4K	0.02%	531
2014 Q4	$871K	Sell	3,193 -294	-8%	-$73.1K	0.01%	587
2014 Q3	$678K	Buy	3,487 +67	+2%	+$14.6K	0.01%	587
2014 Q2	$837K	Buy	3,420 +120	+4%	+$27.1K	0.01%	525
2014 Q1	$875K	Buy	3,300 +227	+7%	+$86.9K	0.01%	490
2013 Q4	$1.08M	Buy	3,073 +60	+2%	+$23.1K	0.02%	421
2013 Q3	$1.6M	Buy	3,013 +80	+3%	+$27.4K	0.03%	350
2013 Q2	$667K	Buy	+2,933	New	+$577K	0.01%	425

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DekaBank Deutsche Girozentrale's CLDX Position: Q2 2026 in Review

DekaBank Deutsche Girozentrale held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 25,000 shares worth $782K. The position accounts for ﹤0.01% of the portfolio, ranked #827.

DekaBank Deutsche Girozentrale first reported a position in CLDX in Q2 2013 and has held it in 25 quarters since. The position peaked at $1.6M in Q3 2013. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

DekaBank Deutsche Girozentrale held 25,000 shares of Celldex Therapeutics worth $782K as of Q2 2026.
DekaBank Deutsche Girozentrale left its Celldex Therapeutics share count unchanged in Q2 2026.
Celldex Therapeutics made up ﹤0.01% of DekaBank Deutsche Girozentrale's portfolio in Q2 2026, its #827 holding.
DekaBank Deutsche Girozentrale first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 25 quarters since.
DekaBank Deutsche Girozentrale's Celldex Therapeutics position peaked at $1.6M in Q3 2013.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2026, filed 5 Aug 2026.